

R. Brian Mitchell, M.D.

CURRICULUM VITAE

support@medsurityexperts.com

PROFESSIONAL EXPERIENCE

- 20 years of clinical practice with Virginia Cancer Institute (VCI) in Richmond, Virginia
- President and Managing Partner of VCI January 2014 – January 2017
- Assistant Professor of Medicine, Virginia Commonwealth University 1992-1999
- 30 years of practicing clinical hematology, oncology, and internal medicine
- Strong focus on bedside manner, quality of life, supportive care, and patient independence
- One of eight finalists and the only oncologist nominated for “Best Physician in Richmond” August, 2017
- Experience with basic science research, clinical research, phase I development
- Since January 2018, part-time clinical practice at VCI and part-time managing my own company engaged in:
 - Locum tenens clinical practice for:
 - Community Medical Center, Missoula, MT- 2/18 – 4/18
 - Bay Area Medical Center, Marinette, WI- 6/18- Present
 - Great Plains Health, North Platte, NE- 5/19-9/19
 - MidMichigan Health, Midland, MI- 11/19-1/20
 - Bronson Battle Creek, Battle Creek, MI – 1/20
 - medical-legal consulting
 - medical case file review
 - Advocates for Private and Independent Medicine - promoting self-directed medical care

EDUCATION

- 1981-85 M.D. Duke University School of Medicine (AOA)
- 1977-81 A.B. Duke University Degree (Magna cum laude)

POSTGRADUATE TRAINING

- 1988-92 Fellow in Hematology/Oncology University of Chicago Hospital, Chicago, IL
- 1985-88 Intern and Resident in Internal Medicine Johns Hopkins Hospital Baltimore, MD

SPECIALTY CERTIFICATION

- American Board of Internal Medicine 2008
- Subspecialty Certification in Medical Oncology 1991, 2001, 2011
- Subspecialty Certification in Hematology 1992, 2002, 2012

MEDICAL LICENSURE

- Virginia
- Wisconsin
- Montana
- Nebraska
- Michigan

CURRENT POSITION AND ADDRESS

Virginia Cancer Institute
6605 West Broad Street, Suite A
Richmond, VA 23230
804-287-3000

Mid-Atlantic Medical Consulting, LLC
14241 Midlothian Turnpike, #512
Midlothian, VA 23113
804-667-8903

PERSONAL INFORMATION

- Born: March 7, 1959, Columbus, Ohio
- US citizen
- Married, 3 children
- Home address and telephone number:
13421 Stonegate Road
Midlothian, VA 23113
804-379-4997 (h)
804-833-8903 (c)

ACADEMIC APPOINTMENTS

- 1992-1999 Assistant Professor of Medicine, Department of Medicine, Medical College of Virginia, Virginia Commonwealth University

CLINICAL EXPERIENCE

- Locum Tenens work through Hayes Locums February 2018 -
- Clinical Hematology/Oncology Practice with Virginia Cancer Institute, Richmond, VA 1999 -
- Principal, Chest Tumor Conference, Henrico Doctor's Hospital, Richmond 2012 - 2017
- Academic Clinical Hematology/Oncology Practice at MCV/VCU 1992 - 1999
- Attending Physician, Bone Marrow Transplant Unit, MCV/VCU 1992-99
- Principal, Chest Tumor Conference, MCV/VCU 1992- 1999

MEMBERSHIP IN PROFESSIONAL SOCIETIES

- 1991 - American Society of Clinical Oncology
- 1992 - 97 American Association for Cancer Research
- 1989 - American College of Physicians
- 1992 - 2005 International Association for the Study of Lung Cancer
- 1993 - 2007 American Society of Hematology
- 1995 - 2007 Virginia Thoracic Society
- 1998 - Richmond Academy of Medicine
- 2012 - 15 American Association for Physician Leadership
- 2016 - Association of American Physicians and Surgeons

CLINICAL RESEARCH EXPERIENCE

- Chairman, Clinical Trials Review Committee, Massey Cancer Center, VCU, 1993-99
- Investigator-Initiated clinical trial: A phase I study of a unique schedule of dacarbazine and carmustine, University of Chicago, 1991

External Grants for Investigator-Initiated Clinical Trials

- Hoechst-Roussel Pharmaceuticals, Inc. Grant-in-aid (\$32,200): "A Pilot Study of Pentoxifylline for the Treatment of Cancer Cachexia in Patients with Lung Cancer"
- Bristol Myers Squibb Company. (\$8,000): "Biweekly Therapy with Paclitaxel and Carboplatin for Patients with Advanced Non-Small-Cell Lung Cancer"
- 1997 Alza Pharmaceuticals (\$76,000): "A Pilot Trial of Amifostine to Ameliorate the Toxicities of Paclitaxel/Carboplatin for Patients with Advanced Non-Small-Cell Lung Cancer"

Local Principal Investigator or Sub-Investigator (see below)***

INVITED LECTURES

"Multimodality Modality Treatment of Stage III Lung Cancer"
St. Catherine's Hospital Muncie, Indiana 3/92

"Combined Modality Therapy Using Hyperfractionated Radiotherapy for Esophageal Cancer"
MCV Tumor Board - Concept Review Series, 2/94

"Factor VIII inhibitor"
Medical Grand Rounds (Clinical-Pathologic Conference), MCV, 2/94

"Hematologic Manifestations of Disease"
Annual Spring Institute of the Southside Medical Society, Farmville, Virginia, 4/96

"Combined Modality Therapy of Thoracic Malignancies"
Riverside Hospital Grand Rounds, Newport News, VA, 7/96

"Bronchogenic Carcinoma: The Role of the Oncologist"
Virginia Thoracic Society, Fall Conference, Richmond, VA, 9/29/96

"An Electronic Medical Records System for Oncologists"
Virginia Association of Hematologists & Oncologists
Annual Meeting, Richmond, VA, 10/24/97

"Supportive Care for Patients with Non-Small-Cell Lung Cancer"
1st Annual MCV/VCU Advances in Cancer Therapy, Williamsburg, VA 11/8/97

"Thrombocytopenia and Thrombocytosis"
Grand Rounds Southside Regional Medical Center, Petersburg, VA 12/97

"Combined Modality Therapy for Lung Malignancies"
Oncology Symposium, Rockingham Memorial Hospital, Harrisonburg, VA 11/98

"Advances in Therapy of non-Small Cell Lung Cancer"
Tumor Board Conference, Memorial Regional Medical Center Richmond, VA 9/99

“Cancer Pain”

St. Mary’s Hospital Nursing Pain Conference, Richmond, VA 9/29/15

“New Treatments for Cancer & The Promise of Clinical Trials”

Community Cancer Survivor’s Symposium, Richmond, VA, 11/7/15

OTHER SCHOLARLY, RESEARCH OR ADMINISTRATIVE EXPERIENCE

Administrative

- President and Managing Partner of VCI January 2014 – January 2017
 - 25 providers covering 7 offices and 9 hospitals in 3 cities
 - Responsible for evaluating entrepreneurial opportunities, setting the strategic direction of the practice, managing physician and employee performance issues, and organizing clinical programs
- Management Committee, Virginia Cancer Institute, 2008 -
- Laboratory Director, Virginia Cancer Institute Flow Cytometry Laboratory 2015 -
- Director of Medical Oncology, Bon Secours St. Mary’s Hospital, 2003- 2005
- Vice-Chair for Clinical Affairs, Division of Hematology/Oncology, VCU, 1997-99
- Coordinator, Outpatient Medical Oncology Services at VCU, 1996-97
- Medical Oncologist, Chest Tumor Center, VCU, 1992-99
- Oncology Subcommittee of Pharmacy and Therapeutics Committee, MCV/VCU, 1995-97
- Coordinator of Hematology/Oncology Divisional Conferences, 1993-95
- Division of Hematology/Oncology Practice Committee, MCV, 1993-95
- Internal Medicine Quality Assessment and Improvement Committee, MCV/VCU, 1994-95
- Internal Medicine Nurse Practitioner Committee, MCV/VCU, 1994-99
- Chairman, Massey Cancer Center Tumor Board, 1993-94

Teaching

- Preceptor, Introduction to Clinical Medicine course, MCV/VCU, 1992-96
- Hematology Lecture Series, Laboratory Preceptor, MS II, MCV/VCU, 1993-94
- Attending Physician, Dalton Hematology/Oncology Clinic, MCV/VCU, 1992-98
- Small group discussion leader, Foundations of Clinical Medicine, MCV, 1997-99

Continuing Education

- “First Annual Workshop on Methods in Clinical Research,” sponsored by ASCO and AACR. Park city, Utah 8/17-8/23/96
- Scientific Chairman: 1st Annual MCV/VCU Advances in Cancer Therapy, Williamsburg, VA 11/8/98

OTHER PROFESSIONAL ACTIVITIES

- Scientific Reviewer: Medical Care Ombudsman Program, 1994 - 1999
- Medical-legal consulting 1999 - present
- Software design - medical documentation systems: Established private company (Clinic Notes LLC), 1997-2001
- Oncology and Hematology file review with:
 - Medical Review Institute of America, 2017 -
 - MES Peer Review 2019 -
- Oncology Clinical Case Reviews for MassiveBio, Inc 2018 -

MEMBERSHIP IN COMMUNITY ORGANIZATIONS

- Vestry, Redeemer Episcopal Church, Midlothian 2011 - 2013

OUTSIDE INTERESTS

- Swimming
- Golf
- Tennis
- Woodworking
- History
- Travel
- Bridge
- Board Games
- Personal Investing

BIBLIOGRAPHY

Original Papers

Hunter, R.F., Mold, N.G., Mitchell, R.B., and Huang, A.T.: Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. Proc. Natl. Acad. Sci. USA, 82: 4823-4827, 1985.

Mitchell, R.B., Wagner, J.E., Karp, J.E., et al: Syndrome of idiopathic hyperammonemia after high dose chemotherapy: Review of nine cases. Am J. Med., 85: 662-667, 1988.

Dolan, M.E., Stine, L., Mitchell, R.B., Moschel, R.C., and Pegg, A.E.: Modulation of mammalian O⁶-alkylguanine DNA-alkyltransferase in vivo by O⁶-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. *Cancer Communications*, 2(11): 371-377, 1990.

Dolan, M.E., Mitchell, R.B., Mummert, C., Moschel, R.C., and Pegg, A.E.: Effect of O⁶ benzylguanine analogs on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. *Cancer Res.*, 51: 3367-3372, 1991.

Richards, J.M., Gilewski, T.A., Ramming, K.A., Mitchell, B., Doane, L.L., and Vogelzang, N.J.: Effective chemotherapy for melanoma after treatment with interleukin-2. *Cancer*, 69: 427-429, 1992.

Mitchell, R.B., Moschel, R.C., and Dolan, M.E.: Effect of O⁶-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis (2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. *Cancer Res.*, 52: 1171-1175, 1992.

Mitchell, R.B., and Dolan, M.E.: Effect of temozolomide and dacarbazine on O⁶-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. *Cancer Chemother. Pharmacol.*, 32: 59-63, 1993.

Mitchell, R.B., Dolan, M.E., Janisch, L., Vogelzang, N.J., Ratain, M.J., and Schilsky, R.L.: Sequential therapy with dacarbazine and carmustine: A phase I study. *Cancer Chemother Pharmacol*, 34: 509-514, 1994.

Mitchell, R.B.: Systemic Therapy for Non-Small-Cell Lung Cancer. *The Virginia Pulmonary Journal*, 3 (2): 1-3, 1997.

Mitchell, R.B. and Smith, T.J. Lessons in supportive care, VIII: Having the chart support your goals, and remind you to ask about palliative care. *Clinical Oncology Alert*, February: 14-16, 1998.

Roa, V., Conner, A. and Mitchell, R.B.: Carboplatin and paclitaxel for previously treated patients with non small cell lung cancer. *Cancer Investigation*, 26 (6): 381-384, 1998.

Hensley, M.L., Schacter, L.M., Lindley, C., et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. *Journal of Clinical Oncology*, 17 (10): 3333-3355, 1999.

Abstracts

Richards, J.M., Gilewski, T.A., Doane, L.L., Mitchell, R.B., Ramming, K., and Vogelzang, N.J.: Active chemotherapy for metastatic melanoma following failure of interleukin-2-based therapy. *Proc. Am. Assoc. Cancer Res.*, 31: 199, 1990.

Mitchell, R.B., and Dolan, M.E. Enhancement of alkylating agent activity in vitro and in vivo by O⁶-benzylguanine. *Clin. Res.*, 38(3): 843A, 1990.

Dolan, M.E., Mitchell, R.B., Moschel, R.C., and Pegg, A.: Effect of O⁶-benzylguanine analogues on O⁶-alkylguanine-DNA alkyltransferase activity and on the sensitivity of cells to alkylating agents. *Proc. Amer. Assoc. Cancer Res.*, 32: 375, 1991.

Dolan, M.E., Mitchell, R.B., Moschel, R.C., and Pegg, A.E.: Effect of O⁶-benzylguanine on O⁶-alkylguanine-DNA alkyltransferase activity in vivo and on the sensitivity of human glioma xenografts to chloroethylnitrosoureas. Ninth International Conference on Brain Tumor Research and Therapy, Asilomar, California, 1991.

Mitchell, R.B., and Dolan, M.E.: Enhancement of carmustine activity by inhibition of O⁶-alkylguanine-DNA alkyltransferase with dacarbazine or O⁶-benzylguanine. *Clin. Res.*, 39(3): 747A, 1991.

Mitchell, R.B., Dolan, M.E., Janisch, L., Ratain, M.J., and Schilsky, R.L. A phase I study of a unique schedule of dacarbazine and carmustine. *Proc. Amer. Assoc. Cancer Res.*, 33: 236, 1992.

Mitchell, R.B., Chitre, A.A., and Dolan, M.E. Effect of temozolomide or dacarbazine on the sensitivity of human tumor cells and xenografts to carmustine. *Proc. Amer. Assoc. Cancer Res.*, 33: 485, 1992.

Dolan, M.E., Mitchell, R.B., Pegg, A.E., Moschel, R.C., and Grindy, G.B.: Effect of O⁶-benzylguanine on the sensitivity of human tumor xenografts to BCNU. *Proc. Amer. Assoc. Cancer Res.*, 33: 484, 1992.

Mitchell, R.B., Goss, G., Guarino, M., Keaton, M., Hammond, N., Ginizio, M., and Gray, J. Phase II trial of bisnafide in advanced non-small cell lung cancer. *Proc. Amer. Soc. of Clinical Oncology*, 15: 404, 1996.

Roa, V., Conner, A., and Mitchell, R.B. Carboplatin and paclitaxel for chemotherapy-naïve patients with advanced non-small cell lung cancer. *Proc. Amer. Soc. of Clinical Oncology*, 15: 404, 1996.

Roa, V., Conner, A., and Mitchell, R.B. Carboplatin and paclitaxel for advanced non-small cell lung cancer in previously treated patients. *Proc. Amer. Soc. of Clinical Oncology*, 15: 403, 1996.

Swisher, K.N., Ulmer, D.L., Carpenter, W., Mitchell, R.B., Wan, T.H., Dowdy, M., and Smith, T.J. Patient indemnification as a way to involve patients in economic decision-making about their care: barriers in the current system. *Proc. Amer. Soc. of Clinical Oncology*, 15: 328, 1996.

Mitchell, R.B. A simple computer based clinic note system generates a cumulative record at each visit and saves physician and transcriptionist time. *Proceedings ASCO*. 16: 425a, 1997.

Conner, A.C. and Mitchell, R.B. Biweekly carboplatin and paclitaxel for advanced non small cell lung cancer. *Proceedings ASCO*. 16: 465a, 1997

Mitchell, R.B. Amifostine to ameliorate the neurotoxicity of carboplatin/paclitaxel for advanced non-small-cell lung cancer. *Proceedings ASCO* 17:1998

Book Chapters

Mitchell, R.B., Ratain, M.J., and Vogelzang, N.J.: Experimental rationale for continuous infusion chemotherapy. In JJ Lokich, ed: *Cancer chemotherapy by infusion*. Chicago: Precept Press, Inc., 1990, p. 3-34.

Mitchell, R.B., Ratain, M.J., and Vogelzang, N.J.: Experimental rationale for continuous infusion chemotherapy. In M Rotman and CJ Rosenthal, eds: *Concomitant continuous infusion chemotherapy and radiation*. Berlin: Springer-Verlag, 1991, p. 13-27.

Mitchell, R.B., and Hoffman, P.C.: Anemia, leukopenia, and elevated blood counts. In JB Hall, GA Schmidt, and LDH Wood, eds: *Principles of Critical Care Medicine*. New York: McGraw-Hill Publishing Co., 1992, pp. 1807-1817.

Mitchell, R.B., and Hoffman, P.C.: Anemia, leukopenia, and elevated blood counts. In JB Hall, GA Schmidt, and LDH Wood, eds: *Principles of Critical Care Medicine*, 2nd edition. New York: McGraw-Hill Publishing Co., 1998, pp. 1033-1042.

Editorials

Smith, T.J., Hillner, B.E., and Mitchell, R.B. Decision analysis in non-small-cell lung cancer: Not back to the drawing modeling board, back to the bedside. *Journal of Clin. Oncol.*, 15: 870-872, 1997.

Smith, T.J. and Mitchell, R.B. The Mather et al Article Reviewed. *Oncology* 12: 210-216, 1998

CLINICAL RESEARCH

*****Local Principal Investigator**

1994-96 MCV principal investigator, "A Phase II Multicenter Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of DMP 840 Given Every Four Weeks in Patients with Advanced Non-Small Cell Lung Cancer"

1995-97 Investigator, "Effect of Case Management Alternatives on the Satisfaction, Quality of Life, and Cost of Care for End-Stage Metastatic Cancer Patients"

An Open-label, Multicenter, Randomized Phase III, Comparator, Study of Oral Topotecan vs IV Topotecan For Second-Line Therapy in Patients with SCLC Who have Relapsed Greater than or Equal to 90 Days after Completion of First-Line Therapy.

A Randomized Phase 3 Trial of ALIMTA® and Cisplatin versus GEMZAR® and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sub-investigator

A Multicenter phase III randomized trial comparing Docetaxel in combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin and Cyclophosphamide followed by Docetaxel (AC→T) as adjuvant treatment of operable breast cancer Her2Neu negative patients with positive axillary lymph nodes.

A Multi-Center Phase III Randomized, Controlled Study Of Theratope® Vaccine For Metastatic Breast Cancer

Phase III, Randomized Study of Epirubicin/Cyclophosphamide Followed by Taxane (Sequential Chemotherapy) versus Epirubicin/Taxane (Concurrent Chemotherapy) as Adjuvant Treatment for Operable, Node-Positive Breast Cancer

A Phase III Multicenter, Randomized, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF, (Bevacizumab) in Combination With Standard Chemotherapy in Subjects with Metastatic Colorectal Cancer.

A Randomized Phase II Trial of Gemcitabine Plus Paclitaxel Vs. Gemcitabine Plus Weekly Paclitaxel in the Treatment of Advanced or metastatic Non-Small Cell Lung Cancer.

Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) versus Gemcitabine HCL in Chemonaive Pancreatic Cancer Patients

Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients that have Progressive Disease Following Gemcitabine HCl Treatment.

Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) versus most appropriate therapy in Refractory Pancreatic Cancer Patients

A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating The Efficacy, Safety And Pharmacokinetics of RhuMAb VEGF (Bevacizumab) In Combination With Capecitabine Chemotherapy In Subjects With Previously Treated Metastatic Breast Cancer.

A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF, a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial growth factor, in combination with 5-Fluorouracil and Leucovorin Chemotherapy in Subjects with Metastatic Colorectal Cancer who are not Optimal Candidates for First-Line CPT-11.

A Phase 3 Trial of ALIMTA vs. Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Were Previously Treated with Chemotherapy

Prospective, Randomized, Controlled, Double-Blind, Multi-Center Study of G17DT Immunogen in Combination with Gemcitabine versus Placebo in Combination with Gemcitabine in Previously Untreated Subjects with Locally Advanced (Nonresectable Stage II and III), Recurrent Disease Following Primary Resection, or Metastatic (Stage IV) Adenocarcinoma of the Pancreas

Protocol Trastuzumab (Herceptin) And Either Vinorelbine (Navelbine) Or Taxane-based Chemotherapy In patients with HER2 Overexpressing Metastatic Breast Cancer

Randomized, Open-Label Phase III Trial of Chemotherapy with Carboplatin and Paclitaxel versus Carboplatin and Paclitaxel in combination with ISIS, An antisense Inhibitor of Protein Kinase C Alpha, in patients with advanced previously untreated NSCLC

A Multicenter, Randomized, Controlled, Prospective Trial of the Safety and Efficacy of Ferrlecit in Anemic Cancer Patients who are Receiving Acute Chemotherapy and Epoetin as Compared to Oral Iron and No Treatment

A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel) Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer

Actimmune® (Interferon gamma-1b) in Combination With Chemotherapy (Carboplatin/Paclitaxel) for First-line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma

Randomized Phase III Trial Comparing Targretin® Capsules/Carboplatin/Paclitaxel Versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized, Phase II Trial of Two Chemotherapy Combination Regimens (Docetaxel/ Irinotecan or Gemcitabine/Irinotecan with or without Celecoxib) in Patients with Advanced Non-Small Cell Lung Cancer that has Failed One Prior Regimen of Anti-Cancer Treatment

Open-Label, Phase II Trial of the Immunological Response Rate, Safety, and Tolerability of THERATOPE® Vaccine in Subjects with Metastatic Breast Cancer Undergoing Treatment with Aromatase Inhibitors

Sandostatin LAR® Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea

CALGB 40101 - Cyclophosphamide and Doxorubicin (CA) (4 vs 6 Cycles) Versus Paclitaxel (12 Weeks vs 18 Weeks) As Adjuvant Therapy for Women with Node-Negative Breast Cancer:

NCIC CTG BR.19 - A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD 1839 (Iressa) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer

Open-Label Study of ALIMTA (pemetrexed) in Combination with Cisplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma

SWOG Protocols – N9831, C9581, C9741, S0200, S0124

NSABP Protocols – B-33, C-07, C-05, B-28, B-36

A Randomized, Open-label Study of Epoetin Alfa (Procrit) versus Darbepoetin Alfa (Aranesp) to evaluate Hematologic Response Rate in Anemic Cancer Patients Receiving Chemo.

A Randomized, Double-Blind, Placebo Controlled, Phase III Study in Patients with Metastatic Adenocarcinoma of the Colon or Rectum Who are Receiving First-Line Chemotherapy with Oxaliplatin/5-fluorouracil/Leucovorin and PTK787/ZK 222584 or Placebo.

An Open-labeled, Phase II/III Study of Rituximab in Combination with Recombinant Human IL-2 for Relapsed Low Grade or Follicular Non-Hodgkin's Lymphoma in Subjects Who Have Previously Failed Rituximab.

A Multicenter Open-Label Randomized, Three Arm Study of 5-Fluorouracil (5-FU) Plus Leucovorin (LV) or Oxaliplatin or a Combination of 5-FU/LV + Oxaliplatin as a Second-Line Treatment of Metastatic Colorectal CA.

ECOG E6201 – Phase III, Randomized Study of Gemcitabine [fixed-dose rate infusion] & Oxaliplatin (NSC 266046) versus Gemcitabine [30 minute infusion] in Pancreatic Carcinoma.

A Randomized Placebo Controlled Study of OSI-774 (TARCEVA™) Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

A Two-Stage Trial of STA-4783 in Combination with Weekly Paclitaxel for Treatment of Patients with Metastatic Melanoma

A Phase III Randomized, Controlled Study to Evaluate the Safety and Efficacy of PANVAC™ - VF in Combination with GM-CSF Versus Best Supportive Care or Palliative Chemotherapy in Patients with Metastatic (Stage IV) Adenocarcinoma of the Pancreas Who Have Failed a Gemcitabine-Containing Chemotherapy Regimen